PROCEPT BioRobotics announced a 19% increase in revenue to $94.5 million for Q2 2026, driven by higher U.S. system and handpiece sales and international revenue growth. The company delivered 65 HYDROS robotic systems in the U.S., including 14 replacements, and saw a 21% rise in U.S. procedures. Gross margin improved to 66%, supported by pricing discipline and a tariff refund, though net loss widened to $26.9 million due to increased operating expenses. PROCEPT reaffirmed its full-year 2026 revenue guidance of $390-$410 million and expects U.S. procedure volume growth of 25-29%, focusing on advancing prostate disease treatment with AI-powered robotic technology.
Bitcoin's recent price recovery is supported by significant institutional investment, particularly through regulated ETFs, signaling a shift toward long-term ownership. Despite some volatility and a U.S. legislative setback on crypto regulation, infl...
The First Trust High Yield Opportunities 2027 Term Fund (FTHY) is experiencing near-term volatility and weak distribution coverage, with its discount widening despite an approaching liquidation date. However, the fund's term structure may lead to a v...
Glassnode's Altcoin Cycle Signal rose to 86 in June, indicating altcoins outperform Bitcoin, mainly due to Bitcoin's 18% drop rather than strong altcoin demand. By early July, the signal confirmed genuine altcoin strength, but by September, despite a...
The Bitwise Solana Staking ETF (BSOL) attracted over $60 million in new investments in the last two days, raising its assets under management to an all-time high of more than $1.2 billion. This surge reflects growing investor confidence in Solana's p...
Zappin, a new Telegram-based trading bot, launched on Robinhood Chain on September 21, allowing users to swap tokens via Uniswap and receive 90% of their trading fees back in ETH for 30 days. This promotion aims to attract early users to Robinhood's ...
